Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for High-risk acute lymphoblastic leukaemia in children (high-risk B-ALL and T-ALL), drawn from the whole corpus: 4 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No antibody or cell therapy target in routine use for T-ALL.
Which high-risk children still need transplant once immunotherapy clears residual disease.
Nothing recorded yet.
Background: Minimal / molecular residual disease (MRD). Also on OnCo: Treatment journeys · Survivorship planner.
Asparaginase toxicity and osteonecrosis in adolescents receiving the most intensive regimens.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 10 changes by month →When this page itself was last checked or edited.
3-year OS 85% vs 68%; HR 0.
A milestone in how this cancer is treated.
Bortezomib did not significantly improve four-year event-free survival for the whole group (83.
A milestone in how this cancer is treated.
Nelarabine improved disease-free survival in T-cell acute lymphoblastic leukaemia, and Capizzi methotrexate outperformed high-dose methotrexate.